Current Protocols in Pharmacology

Individual Online Subscriptions are now available! Visit the How to Order page for more information.

What's New in Current Protocols in Pharmacology
Supplement 60, March 2013

Unit 2.9 The Human Kinome and Kinase Inhibition
         Abstract | Full Text:  HTML   PDF

Unit 5.64 Cigarette Smoke Exposure as a Model of Inflammation Associated with COPD
         Abstract | Full Text:  HTML   PDF

Unit 9.17 Overview of Determination of Biopharmaceutical Properties for Development Candidate Selection
         Abstract | Full Text:  HTML   PDF

Unit 14.23 Patient-Derived Models of Human Breast Cancer: Protocols for In Vitro and In Vivo Applications in Tumor Biology and Translational Medicine
         Abstract | Full Text:  HTML   PDF

Unit 14.24 Discovery of Biologically Active Oncologic and Immunologic Small Molecule Therapies using Zebrafish: Overview and Example of Modulation of T Cell Activation
         Abstract | Full Text:  HTML   PDF

Developed by industry experts in the areas of drug discovery and safety pharmacology, Current Protocols in Pharmacology is a "best-practices" collection of lab protocols that can help anyone—from the novice investigator to seasoned pro—design and run successful research projects with maximum efficiency.

Updated every three months in all formats, CPPharm is constantly evolving to keep pace with the very latest discoveries and developments. A year of these quarterly updates is included in the initial CPPharm purchase price. That's 530 pages of new (64%) and revised (36%) content on average every year since the initial publication of the work in June 1998! Presently three volumes in its looseleaf print version, CPPharm...

• covers the full range of molecular, cellular, physiological, and chemical techniques used for the discovery and development of novel therapeutics.
• presents state-of-the-art techniques for high-throughput screening methods, including FLIPR, receptor-binding assays, enzyme assays, and an array of preclinical models of disease.
• offers topical guideline overviews for assessment of drug efficacy and side effect liability, supported with appropriate protocols used by the industry.

Edited by: S.J. Enna, Editor-in-Chief (University of Kansas Medical Center); Michael Williams, Editor-in-Chief (Northwestern University Feinberg School of Medicine); Roger Frechette (New England PharmAssociates, LLC); Terry Kenakin (University of North Carolina School of Medicine); Paul McGonigle (GlucoNova, LLP); Bruce Ruggeri (Teva Pharmaceuticals Industries, Ltd.); Guest Editor: Alan D. Wickenden (Janssen Research & Development, LLC); Past Editors: John F. Barrett, James Ellis, John W. Ferkany, Paul Moser, Roger D. Porsolt, James P. Sullivan; Past Guest Editor: Brendan J. Canning

Series Editor: Gwen Taylor

While the authors, editors, and publisher believe that the specification and usage of reagents, equipment, and devices, as set forth in this book, are in accord with current recommendations and practice at the time of publication, they accept no legal responsibility for any errors or omissions, and make no warranty, express or implied, with respect to material contained herein. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. This is particularly important in regard to new or infrequently employed chemicals or experimental reagents. Moreover, the information presented herein is not a substitute for professional judgment, especially as concerns any applications in a clinical setting or the interpretation of results thereby obtained.